Outcomes of Neoadjuvant Therapy for Rectal Cancer in a Tertiary Asian Institute

Outcomes of Neoadjuvant Therapy for Rectal Cancer in a Tertiary Asian

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05607186

Enrollment

Registered

2022-11-07

Start date

2011-01-01

Completion date

2019-12-31

Last updated

2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncology, Rectal Cancer

Brief summary

This is a retrospective cohort study that aims to evaluate the correlation of magnetic resonance tumour regression grade (mrTRG) and pathological TRG (pTRG) of locally advanced rectal cancer after neoadjuvant long course chemoradiotherapy as well as the prognostic value of mrTRG on survival.

Interventions

RADIATIONneoadjuvant long course chemoradiotherapy

neoadjuvant long course chemoradiotherapy consist of radiosensitizing 5FU or capecitabine and 50.4 Gy in 28 fractions over 5 weeks

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Rectal cancer * At least 1 high risk feature on MRI * Undergo long course neoadjuvant chemoradiotherapy (LCCRT)

Exclusion criteria

* metastatic disease * Patients who undergo short course radiotherapy * Patients without a repeat MRI after completion of LCCRT

Design outcomes

Primary

Measure	Time frame
Correlation between mrTRG and pTRG	Between 1 Jan 2011 to 31 Dec 2016

Secondary

Measure	Time frame
Prognostic value of mrTRG on survival outcomes of rectal cancer patients	Between 1 Jan 2011 to 31 Dec 2016

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026